1. 413PDPhase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma. (23rd October 2018) Authors: Krebs, M; Lopez, J; El-Khoueiry, A; Bang, Y-J; Postel-Vinay, S; Abidah, W; Im, S-A; Khoja, L T; Standifer, N; Jones, G N; Marco-Casanova, P; Frewer, P; Berges, A; Cheung, A; Stephens, C; Felicetti, B; Dean, E; Pierce, A; Hollingsworth, S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA2TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI. (24th November 2019) Authors: Han, J-Y; Sequist, L V; Ahn, M-J; Cho, B C; Yu, H; Kim, S-W; Yang, J C-H; Lee, J S; Su, W-C; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, R B; Mellemgaard, A; Frewer, P; Ou, X; Oxnard, G Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗